Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEVANTE phase 2b inhaled AZD8630 dose-ranging study in uncontrolled asthma
NL-OMON57136Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- May 2025
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of azd8630 in asthma (4 arms), sponsored by AstraZeneca. Primary endpoint: Asthma worsening and time to worsening. Started May 2025; status: recruiting.
02
Drugs
azd8630
03
Conditions
asthma
Beyond the preview
Go deeper on NL-OMON57136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON57136.